Driven to transform the lives of patients and families affected by rare diseases of the complement alternative pathway.
Learn MoreAt Achillion, we are driven to transform the lives of patients and families affected by rare diseases of the complement system, an integral part of the innate immune system. Scientific and clinical evidence has implicated the complement system, and specifically the complement alternative pathway in numerous devastating diseases and conditions. Our principal focus at Achillion is to advance our clinical-stage portfolio of orally administered factor D inhibitors into late-stage development and potential commercialization for patients with devastating rare disorders of the complement system. We currently have three clinical stage, oral factor D inhibitors, ACH-4471, ACH-5228, and ACH-5548.